Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rasmussen, LS, Fristrup, CW, Jensen, BV, Pfeiffer, P, Weber, B, Yilmaz, MK, Poulsen, LØ, Ladekarl, M, Østerlind, K, Larsen, JS, Skuladottir, H, Bøgsted, M & Falkmer, UG 2021, 'Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study', Pancreas, vol. 50, no. 5, pp. 685-695. https://doi.org/10.1097/MPA.0000000000001833

APA

Rasmussen, L. S., Fristrup, C. W., Jensen, B. V., Pfeiffer, P., Weber, B., Yilmaz, M. K., Poulsen, L. Ø., Ladekarl, M., Østerlind, K., Larsen, J. S., Skuladottir, H., Bøgsted, M., & Falkmer, U. G. (2021). Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Pancreas, 50(5), 685-695. https://doi.org/10.1097/MPA.0000000000001833

CBE

Rasmussen LS, Fristrup CW, Jensen BV, Pfeiffer P, Weber B, Yilmaz MK, Poulsen LØ, Ladekarl M, Østerlind K, Larsen JS, Skuladottir H, Bøgsted M, Falkmer UG. 2021. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Pancreas. 50(5):685-695. https://doi.org/10.1097/MPA.0000000000001833

MLA

Vancouver

Author

Rasmussen, Louise S ; Fristrup, Claus W ; Jensen, Benny V ; Pfeiffer, Per ; Weber, Britta ; Yilmaz, Mette K ; Poulsen, Laurids Ø ; Ladekarl, Morten ; Østerlind, Kell ; Larsen, Jim S ; Skuladottir, Halla ; Bøgsted, Martin ; Falkmer, Ursula G. / Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age : A Nationwide Real-World Danish Registry Study. In: Pancreas. 2021 ; Vol. 50, No. 5. pp. 685-695.

Bibtex

@article{aeacf4b347354faab86a7442cbbb3dbe,
title = "Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study",
abstract = "OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.",
keywords = "age, palliative chemotherapy pattern, pancreatic cancer, registry study, second-line treatment, survival",
author = "Rasmussen, {Louise S} and Fristrup, {Claus W} and Jensen, {Benny V} and Per Pfeiffer and Britta Weber and Yilmaz, {Mette K} and Poulsen, {Laurids {\O}} and Morten Ladekarl and Kell {\O}sterlind and Larsen, {Jim S} and Halla Skuladottir and Martin B{\o}gsted and Falkmer, {Ursula G}",
note = "Copyright {\textcopyright} 2021 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2021",
month = may,
day = "22",
doi = "10.1097/MPA.0000000000001833",
language = "English",
volume = "50",
pages = "685--695",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age

T2 - A Nationwide Real-World Danish Registry Study

AU - Rasmussen, Louise S

AU - Fristrup, Claus W

AU - Jensen, Benny V

AU - Pfeiffer, Per

AU - Weber, Britta

AU - Yilmaz, Mette K

AU - Poulsen, Laurids Ø

AU - Ladekarl, Morten

AU - Østerlind, Kell

AU - Larsen, Jim S

AU - Skuladottir, Halla

AU - Bøgsted, Martin

AU - Falkmer, Ursula G

N1 - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2021/5/22

Y1 - 2021/5/22

N2 - OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.

AB - OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.

KW - age

KW - palliative chemotherapy pattern

KW - pancreatic cancer

KW - registry study

KW - second-line treatment

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85108021068&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001833

DO - 10.1097/MPA.0000000000001833

M3 - Journal article

C2 - 34016900

VL - 50

SP - 685

EP - 695

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -

ID: 68136608